BioSpace News Archive

Drug Development

Freeline’s One Dose Gene Therapy could Transform Hemophilia B Treatment

Freeline Therapeutics’ hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.

July 21, 2022
·
2 min read
·
Vanessa Doctor, MS
Drug Development

“Imagine” a World without Daily Insulin Injections for Type 1 Diabetes

In a recent interview with BioSpace, Imagine Pharma CEO Ngoc Thai shared the vast potential posed by a polypeptide called IMG-1 to treat Type 1 diabetes.

July 21, 2022
·
5 min read
·
Hayley Shasteen
Drug Development

Mouth and Mind, Intertwined: Study Shows Link between Alzheimer’s and Gum Disease

A new study published in Frontiers in Aging Neuroscience by researchers at Tufts University further supports the theory that there’s a link between gum disease and Alzheimer’s.

July 21, 2022
·
4 min read
·
Mark Terry
Job Trends

Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients

Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients.

July 21, 2022
·
3 min read
Drug Development

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA ® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

July 21, 2022
·
15 min read
Business

Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives

Kallyope and Brightseed have entered a strategic research collaboration to screen plant compounds to identify and validate active agents.

July 21, 2022
·
5 min read
Business

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Joh Hixon to a newly created position as Head of Commercial.

July 21, 2022
·
5 min read
Deals

LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43,000,000 common shares at a price to the public of $1.75 per share.

July 21, 2022
·
6 min read
Deals

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus.

July 21, 2022
·
3 min read
Pharm Country

Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before the US markets open on Thursday, August 4, 2022.

July 21, 2022
·
2 min read